As reported by Law360 (subscription), Allergan has agreed to pay $30 million to settle an antitrust lawsuit filed by Lieff Cabraser and co-counsel on behalf of a group of pharmaceutical purchasers, union benefit plans, and other buyers of Allergan’s blockbuster dry-eye disease drug Restasis. The sweeping litigation accused the drugmaker of misconduct intended to illegally
If You Bought or Provided Reimbursement for the Dry-Eye Disease Drug Restasis® You Could Be Included in a Class Action Lawsuit For more detailed information, visit: www.RestasisLitigation.com Para conseguir una notificación en español, llame a 1-877-868-6810 o visite el sitio web: www.RestasisLitigation.com.
As reported by Law360 (subscription), a New York federal judge has granted class certification in an antitrust lawsuit wherein Lieff Cabraser and co-counsel represent a group of pharmaceutical purchasers, union benefit plans, and other buyers of Allergan’s blockbuster dry-eye disease drug Restasis. The sweeping litigation accuses the drugmaker of misconduct intended to illegally limit competition
As reported in Law360 (subscription), plaintiffs in the multidistrict litigation against pharmaceutical manufacturer Allergan have successfully defeated a motion to dismiss the case alleging antitrust violations with respect to the sale and marketing of dry-eye drug Restasis. The Court’s ruling favored a group of pharmaceutical purchasers and union benefit plans accusing Allergan of misconduct intended